CD45RA(+)CD62L(-) ILCs in human tissues represent a quiescent local reservoir for the generation of differentiated ILCsShow others and affiliations
2022 (English)In: Science immunology, E-ISSN 2470-9468, Vol. 7, no 70, article id eabj8301Article in journal (Refereed) Published
Abstract [en]
Innate lymphoid cells (ILCs) are highly plastic and predominantly mucosal tissue-resident cells that contribute to both homeostasis and inflammation depending on the microenvironment. The discovery of naive-like ILCs suggests an ILC differentiation process that is akin to naive T cell differentiation. Delineating the mechanisms that underlie ILC differentiation in tissues is crucial for understanding ILC biology in health and disease. Here, we showed that tonsillar ILCs expressing CD45RA lacked proliferative activity, indicative of cellular quiescence. CD62L distinguished two subsets of CD45RA(+) ILCs. CD45RA(+)CD62L(+) ILCs (CD62L(+) ILCs) resembled circulating naive ILCs because they lacked the transcriptional, metabolic, epigenetic, and cytokine production signatures of differentiated ILCs. CD45RA(+)CD62L(-) ILCs (CD62L(-) ILCs) were epigenetically similar to CD62L(+) ILCs but showed a transcriptional, metabolic, and cytokine production signature that was more akin to differentiated ILCs. CD62L(+) and CD62L(-) ILCs contained uni- and multipotent precursors of ILC1s/NK cells and ILC3s. Differentiation of CD62L(+) and CD62L(-) ILCs led to metabolic reprogramming including up-regulation of genes associated with glycolysis, which was needed for their effector functions after differentiation. CD62L(-) ILCs with preferential differentiation capacity toward IL-22-producing ILC3s accumulated in the inflamed mucosa of patients with inflammatory bowel disease. These data suggested distinct differentiation potential of CD62L(+) and CD62L(-) ILCs between tissue microenvironments and identified that manipulation of these cells is a possible approach to restore tissue-immune homeostasis.
Place, publisher, year, edition, pages
AMER ASSOC ADVANCEMENT SCIENCE , 2022. Vol. 7, no 70, article id eabj8301
National Category
Immunology
Identifiers
URN: urn:nbn:se:liu:diva-186477DOI: 10.1126/sciimmunol.abj8301ISI: 000800108000011PubMedID: 35427178OAI: oai:DiVA.org:liu-186477DiVA, id: diva2:1676933
Note
Funding Agencies|European Research Council (ERC) under the European Union [850963]; Erling-Persson Family Foundation; Swedish Research Council; Swedish Cancer Society; Swedish Foundation for Strategic Research; Knut and Alice Wallenberg Foundation; Karolinska Institutet; Childhood Cancer Foundation; Goran Gustafsson Foundation
2022-06-272022-06-272022-06-27